4.7 Article

Moxifloxacin rescues SMA phenotypes in patient-derived cells and animal model

Journal

CELLULAR AND MOLECULAR LIFE SCIENCES
Volume 79, Issue 8, Pages -

Publisher

SPRINGER BASEL AG
DOI: 10.1007/s00018-022-04450-8

Keywords

Spinal muscular atrophy; Drug repurposing; SMN2 splicing; Motoneurons; SMA delta7 mice

Funding

  1. CRUE-CSIC
  2. Springer Nature
  3. French Muscular Dystrophy Association (AFM-Telethon) [22346]
  4. Generalitat Valenciana
  5. ERDF funds (OP ERDF of Comunitat Valenciana 2014-2020)

Ask authors/readers for more resources

In this study, we discovered that moxifloxacin has the potential to treat spinal muscular atrophy (SMA). It improves the molecular and phenotypical defects associated with SMA and increases SMN protein levels, leading to improved motor skills and extended lifespan.
Spinal muscular atrophy (SMA) is a genetic disease resulting in the loss of alpha-motoneurons followed by muscle atrophy. It is caused by knock-out mutations in the survival of motor neuron 1 (SMN1) gene, which has an unaffected, but due to preferential exon 7 skipping, only partially functional human-specific SMN2 copy. We previously described a Drosophila-based screening of FDA-approved drugs that led us to discover moxifloxacin. We showed its positive effect on the SMN2 exon 7 splicing in SMA patient-derived skin cells and its ability to increase the SMN protein level. Here, we focus on moxifloxacin's therapeutic potential in additional SMA cellular and animal models. We demonstrate that moxifloxacin rescues the SMA-related molecular and phenotypical defects in muscle cells and motoneurons by improving the SMN2 splicing. The consequent increase of SMN levels was higher than in case of risdiplam, a potent exon 7 splicing modifier, and exceeded the threshold necessary for a survival improvement. We also demonstrate that daily subcutaneous injections of moxifloxacin in a severe SMA murine model reduces its characteristic neuroinflammation and increases the SMN levels in various tissues, leading to improved motor skills and extended lifespan. We show that moxifloxacin, originally used as an antibiotic, can be potentially repositioned for the SMA treatment.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available